

Irene V Bijnsdorp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4436113/publications.pdf>

Version: 2024-02-01

33
papers

1,730
citations

471509

17
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

3775
citing authors

#	ARTICLE	IF	CITATIONS
1	Secreted protein markers in oral squamous cell carcinoma (OSCC). <i>Clinical Proteomics</i> , 2022, 19, 4.	2.1	12
2	Feasibility of phosphoproteomics to uncover oncogenic signalling in secreted extracellular vesicles using glioblastoma-EGFRV8 cells as a model. <i>Journal of Proteomics</i> , 2021, 232, 104076.	2.4	5
3	Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12093.	12.2	182
4	Lipopolysaccharide-regulated secretion of soluble and vesicle-based proteins from a panel of colorectal cancer cell lines. <i>Proteomics - Clinical Applications</i> , 2021, 15, 1900119.	1.6	2
5	Longitudinal stability of urinary extracellular vesicle protein patterns within and between individuals. <i>Scientific Reports</i> , 2021, 11, 15629.	3.3	6
6	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 104-119.	6.9	51
7	Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels. <i>Cancers</i> , 2019, 11, 953.	3.7	6
8	Urinary exosomal proteins as (pan-)cancer biomarkers: insights from the proteome. <i>FEBS Letters</i> , 2019, 593, 1580-1597.	2.8	46
9	Changes in the urinary extracellular vesicle proteome are associated with nephronophthisis-related ciliopathies. <i>Journal of Proteomics</i> , 2019, 192, 27-36.	2.4	22
10	Large-Scale Urinary Proteome Dataset Across Tumor Types Reveals Candidate Biomarkers for Lung Cancer. <i>EBioMedicine</i> , 2018, 30, 5-6.	6.1	5
11	Plasma FGF23 is not elevated in prostate cancer. <i>Clinica Chimica Acta</i> , 2018, 478, 129-131.	1.1	3
12	Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1313091.	12.2	51
13	The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 385-400.	3.8	18
14	Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. <i>Oncotarget</i> , 2017, 8, 4960-4976.	1.8	80
15	Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. <i>Oncotarget</i> , 2016, 7, 22566-22578.	1.8	113
16	Protein Complexes in Urine Interfere with Extracellular Vesicle Biomarker Studies. <i>Journal of Circulating Biomarkers</i> , 2016, 5, 4.	1.3	40
17	miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110. <i>Oncotarget</i> , 2016, 7, 16676-16687.	1.8	20
18	Nontemplated Nucleotide Additions Distinguish the Small RNA Composition in Cells from Exosomes. <i>Cell Reports</i> , 2014, 8, 1649-1658.	6.4	484

#	ARTICLE	IF	CITATIONS
19	Radiosensitization by Thymidine Phosphorylase Inhibitor in Thymidine Phosphorylase Negative and Overexpressing Bladder Cancer Cell Lines. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014, 33, 413-421.	1.1	8
20	The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1273-1283.	2.3	12
21	Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer. <i>World Journal of Urology</i> , 2013, 31, 261-266.	2.2	5
22	Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. <i>Journal of Extracellular Vesicles</i> , 2013, 2, .	12.2	125
23	Profiling of the calcitonin-calcitonin receptor axis in primary prostate cancer: Clinical implications and molecular correlates. <i>Oncology Reports</i> , 2013, 30, 1265-1274.	2.6	9
24	ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. <i>Anticancer Research</i> , 2013, 33, 387-91.	1.1	32
25	A predictive role for noncancerous prostate cells: low connexin-26 expression in radical prostatectomy tissues predicts metastasis. <i>British Journal of Cancer</i> , 2012, 107, 1963-1968.	6.4	10
26	TAS-102: more than an antimetabolite. <i>Lancet Oncology</i> , The, 2012, 13, e518-e519.	10.7	10
27	Analysis of Drug Interactions. <i>Methods in Molecular Biology</i> , 2011, 731, 421-434.	0.9	189
28	Lipophilic Prodrugs and Formulations of Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011, 30, 1168-1180.	1.1	10
29	Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2-deoxyuridine. <i>Investigational New Drugs</i> , 2011, 29, 248-257.	2.6	12
30	Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1047-1057.	4.1	26
31	Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. <i>International Journal of Cancer</i> , 2010, 126, 2457-2468.	5.1	80
32	Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. <i>Cancer Science</i> , 2010, 101, 440-447.	3.9	27
33	Radiosensitizing potential of the selective cyclooxygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. <i>Journal of Neuro-Oncology</i> , 2007, 85, 25-31.	2.9	27